Gynecology

Ovarian / Fallopian / Peritoneal

- Relapsed or Refractory Intolerant to Standard Care
  - CCT5048
    - Phase I/II Study to Evaluate the Safety Pharmacokinetics and Efficacy of BLU-222 as Single Agent in Combination Therapy in Advanced Solid Tumors
    - PI: Dorigo
    - Sponsor: BioEclipse Therapeutics
    - 1st Priority

- Advanced Solid Tumors
  - VAR0243
    - Phase III Study to Evaluate the Safety Pharmacokinetics and Efficacy of BLU-222 as Single Agent in Combination Therapy in Advanced Solid Tumors
    - PI: Telli
    - Sponsor: Blueprint Medicines Corporation

- Recurrent or Refractory
  - ECOG-ACRIN-EAY191-N4
    - Randomized Trial of Selumetinib & Olaparib or Selumetinib Alone in Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
    - PI: Chow
    - Sponsor: National Cancer Institute (NCI)

- Recurrent
  - GYNOPF0018
    - Phase III Study of Replaricin in Combination with Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Advanced Platinum-resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian-Tube Cancer (ROSETTA)
    - PI: Berek
    - Sponsor: Eisai Inc.
    - 2nd Priority

- Platinum Resistant
  - VAR0211
    - Phase III Study to Evaluate the Safety Pharmacokinetics and Efficacy of BLU-222 as Single Agent and in Combination Therapy in Advanced Solid Tumors
    - PI: Telli
    - Sponsor: Blueprint Medicines Corporation

- Platinum Resistant or Refractory
  - VAR0243
    - Phase III Study of Mirvetuximab Soravtansine in Combination with Bevacizumab vs Bevacizumab Alone as Maintenance Therapy in FR-Alpha-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-Based Chemotherapy Plus Bevacizumab
    - PI: Berek
    - Sponsor: ImmunoGen, Inc.

- Platinum Sensitive
  - GYNOVA0058
    - Phase III Randomized Trial of Hyperthermic Intraoperative Chemotherapy (HIPEC) w/ Cisplatin vs No HIPEC at the Time of Interval Cytoreductive Surgery Followed By Niraparib Maintenance in Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, & Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial)
    - PI: Karam
    - Sponsor: GOG Foundation

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu